Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

What You Need To Know Moving Day Tampa Bay fundraising walk is Saturday, May 3; details at bottom of story USF Health is home to Parkinson’s Foundation Center of Excellence Helpline available at ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and ...

Rune Labs, which specializes in precision medicine for Parkinson’s disease (PD), has launched of a clinical program with Parkinson’s Foundation. The goal is to “accelerate the discovery of genetic and ...

Affecting an estimated one million Americans, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S.

An Ohio music conductor is using deep brain stimulation to combat his Parkinson’s disease. Rand Laycock, 70, the director and conductor of a symphony orchestra, was diagnosed just before his ...

Evoke Pharma's abstract on metoclopramide and tardive dyskinesia accepted for presentation at DDW 2025, emphasizing drug safety analysis. Quiver AI Summary Evoke Pharma, Inc. announced that an ...